Biosynthesis of human-type N-glycans in heterologous systems

Betenbaugh, Michael J; Tomiya, Noboru; Narang, Someet; Hsu, John; Lee, Yuan C.

doi:10.1016/j.sbi.2004.09.001

Cited by 62 publications

(45 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general secretory glycoproteins, the high-mannosetype glycans are extensively trimmed by Golgi mannosidases a n d t h e n s u b j e c t e d t o N -a c e t y l g l u c o s a m i n y l a t i o n , galactosylation, sialylation, and/or sulfation in the Golgi apparatus (1,2). In marked contrast, the high-mannosetype glycans of lysosomal enzymes undergo specific modifications of M6P residues in the cis-Golgi.…”

Section: B Role Of P-type Lectins and Mrh Domain-containing Proteinsmentioning

confidence: 99%

“…In eukaryotic cells, N-linked glycoproteins are subjected to diverse modifications and transported through the endoplasmic reticulum (ER) via the Golgi apparatus to their final destinations inside or outside the cell (1,2). The sugar chain is initially introduced by oligosaccharyltransferase as a high-mannose-type tetradecasaccharide (Glc 3 Man 9 GlcNAc 2 ) ( Fig.…”

Section: A Introductionmentioning

confidence: 99%

“…Eventually, the potentially toxic misfolded proteins are degraded by ubiquitin/proteasome system via the so-called ER-associated degradation (ERAD) (11). In plants and animals, the transported glycoproteins with high-mannosetype glycan are further processed by several mannosidases and glycosyltransferases to generate a complex-type glycan in the Golgi apparatus (1,2). The animal lysosomal enzymes are glycoproteins, and modified differently from the normal secretory glycoproteins by the addition of one or more mannose 6-phosphate (M6P) residues to the high-mannosetype glycan in the cis-Golgi (12)(13)(14).…”

Section: A Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Molecular and Structural Basis for Sugar Recognition by Mannose 6-Phosphate Receptor Homology Domain-Containing Lectins and Proteins

Satoh

2012

TIGG

View full text Add to dashboard Cite

N -Linked glycans play important roles in the determination of glycoprotein fates in cells through interactions with a variety of intracellular lectins. Most of the intracellular lectins possess carbohydrate recognition domain, which is homologous to legume lectins or mannose 6-phosphate receptors (MPRs). These lectins are categorized as L-type or P-type lectins. Besides L-type lectins, recently accumulated frontal affinity chromatography and glycan microarray data have demonstrated that P-type lectins and the MPR homology (MRH) domain-containing proteins have distinct sugar-binding specificity profiles. Furthermore, newly emerged three-dimensional structural data have revealed sugar recognition mechanisms at an atomic level. This review summarizes the current state of knowledge of molecular and structural basis for sugar recognition by P-type lectins and MRH domain-containing proteins that control folding, transport, and degradation of N-linked glycoproteins in the secretory pathway.

show abstract

Section: B Role Of P-type Lectins and Mrh Domain-containing Proteinsmentioning

confidence: 99%

Section: A Introductionmentioning

confidence: 99%

Section: A Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular and Structural Basis for Sugar Recognition by Mannose 6-Phosphate Receptor Homology Domain-Containing Lectins and Proteins

Satoh

2012

TIGG

View full text Add to dashboard Cite

show abstract

“…Therefore, using a human DNA sequence does not guarantee that the molecule will be glycosylated as it is when synthesized by the human bodies. The peptide sequence may determine where glycosylation is added to the protein but the mix of glycosyltransferases, within the cell the protein is expressed in and even the conditions under which those cells are cultured will determine what oligosaccharide structures are added to the molecule (Raju et al, 2003;Betenbaugh et al, 2004). Covalent binding between the sugars and the peptide chain is a central part of the structure of glycoproteins.…”

Section: Gene Constructions For Expression In Mammary Glandmentioning

confidence: 99%

Production of recombinant proteins in milk of transgenic and non-transgenic goats

Moura

Melo

Freitas

2011

Braz. arch. biol. technol.

View full text Add to dashboard Cite

Among all the transgenic mammalians produced so far, goats have represented an excellent model of transgenesis when considering the factors such as the market demand for protein, volume of milk produced per lactation and reproductive rate. Various recombinant proteins have been obtained from the transgenic and non-transgenic goats, and among these, human antithrombin, produced by the transgenic goats, was the first recombinant protein of animal origin to be released as a drug for the clinical use in humans. This review reports the aspects inherent to the production of recombinant proteins in the goats, from the production of the animal bioreactors up to the expression of these proteins in their milk.

show abstract

“…An approach for improving the pharmacological properties of higher molecular weight drug candidates, analogous to Lipinski's guidelines for the modification of small molecule drugs, has been applied for protein therapeutics such as recombinant antibodies and protein toxins used in cancer treatment. In these cases, the amino acid sequences of recombinant proteins have been ''humanized'' by genetic engineering to avoid immunogenicity [61,62] and their glycosylation patterns have been modified to increase serum half-life [63,64]. These efforts, undertaken with actual proteins, illuminate design features that can benefit the development of protein mimics, dendrimers.…”

Section: 5mentioning

confidence: 99%

Dendrimers in Cancer Treatment and Diagnosis

Sampathkumar

Yarema

2003

Nanotechnologies for the Life Sciences

View full text Add to dashboard Cite

The sections in this article are Overview Introduction Basic Properties and Applications of Dendrimers Structural Features and Chemical and Biological Properties Basic Features of Dendritic Macromolecules are Inspired by Nature Comparison of the Properties of Dendrimers and Conventional Synthetic Polymers Comparison of the Properties of Dendrimers and Proteins (a Biological Polymer) Dendritic Macromolecules Possess a Wealth of Possible Applications Methods for Dendrimer Synthesis History and Basic Strategies Cascade Reactions are the Foundation of Dendrimer Synthesis Dendrimer Synthesis has Expanded Dramatically in the Past Two Decades Strategies, Cores, and Building Blocks for Dendritic Macromolecules Dendrimers are Constructed from Simple “Building Blocks” The Synthesis of Dendrimers Follows Either a Divergent or Convergent Approach Heterogeneously‐functionalized Dendrimers Basic Description and Synthetic Considerations Glycosylation is an Example of Surface Modification with Multiple Bioactivities Dendrimers in Drug Delivery Dendrimers are Versatile Nano‐devices for the Delivery of Diverse Classes of Drugs Dendritic Drug Delivery: Encapsulation of Guest Molecules Dendrimers have Internal Cavities that can Host Encapsulated Guest Molecules Using Dendrimers for Gene Delivery Release of Encapsulated “Pro‐drugs” Covalent Conjugation Strategies Dendrimers Overcome many Limitations Inherent in Polymeric Conjugation Strategies Dendrimer Conjugates can be Used as Vaccines Release of Covalently‐delivered “Pro‐drugs” Fine‐tuning Dendrimer Properties to Facilitate Delivery and Ensure Bioactivity Delivery Requires Avoiding Non‐specific Uptake “Local” Considerations: Contact with, and Uptake by, the Target Cell Drug Delivery: Ensuring the Biocompatibility of Dendritic Delivery Vehicles Biocompatibility Entails Avoiding “Side Effects” such as Toxicity and Immunogenicity Water Solubility and Immunogenicity Inherent and Induced Toxicity Dendrimers in Cancer Diagnosis and Treatment Dendrimers have Attractive Properties for Cancer Treatment Dendrimer‐sized Particles Passively Accumulate at the Sites of Tumors Multifunctional Dendrimers can Selectively Target Biomarkers found on Cancer Cells Methods for Targeting Specific Biomarkers of Cancer Targeting by Folate, a Small Molecule Ligand Targeting by Monoclonal Antibodies Dendrimers in Cancer Diagnosis and Imaging Labeled Dendrimers are Important Research Tools for Biodistribution Studies Towards Clinical Use: MRI Imaging Agents Steps Towards the Clinical Realization of Dendrimer‐based Cancer Therapies The Stage is now set for Dendrimer‐based Cancer Therapy Boron Neutron Capture Therapy Innovations Promise to Speed Progress “Mix‐and‐Match” Strategy of Bifunctional Dendritic Clusters Towards Therapeutic Exploitation of Glycosylation Abnormalities found in Cancer Towards Targeting Metabolically‐engineered Carbohydrate Epitopes Concluding Remarks Acknowledgments

show abstract

Biosynthesis of human-type N-glycans in heterologous systems

Cited by 62 publications

References 37 publications

Molecular and Structural Basis for Sugar Recognition by Mannose 6-Phosphate Receptor Homology Domain-Containing Lectins and Proteins

Molecular and Structural Basis for Sugar Recognition by Mannose 6-Phosphate Receptor Homology Domain-Containing Lectins and Proteins

Production of recombinant proteins in milk of transgenic and non-transgenic goats

Dendrimers in Cancer Treatment and Diagnosis

Contact Info

Product

Resources

About